Carisma Therapeutics, Inc. (CARM)

In December 2025, Carisma announced its intention to voluntarily delist its common stock from The Nasdaq Stock Market LLC. In October 2025, the stock plunged after receiving a Nasdaq delisting notice. In August 2025, Carisma Therapeutics approved a reverse stock split. In June 2025, Carisma Therapeutics and OrthoCellix entered into a definitive merger agreement. In March 2025, the company announced a strategic restructuring, including a workforce reduction and a pivot to prioritize its in vivo macrophage engineering platform. In December 2024, H.C. Wainwright downgraded the stock from Buy to Neutral following the discontinuation of the lead program, CT-0525.

As a clinical-stage biopharmaceutical company, Carisma Therapeutics, Inc. does not have commercialized products with traditional demand seasonality. The demand for its potential future therapies would be driven by disease prevalence and treatment efficacy rather than seasonal patterns. The company's focus on serious diseases suggests a consistent underlying medical need rather than seasonal fluctuations.

Carisma Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and other serious diseases. Their innovation lies in their chimeric antigen receptor macrophage (CAR-M) and monocyte cell engineering platform, which aims to reprogram macrophages and monocytes to target and destroy diseased cells, particularly in solid tumors. The company's pipeline includes CT-0508, an ex vivo gene-modified autologous CAR-Monocyte cellular therapy designed to treat solid tumors that overexpress HER2; CT-1119, a mesothelin-targeted CAR-Monocyte in Phase I clinical trial for advanced mesothelin-positive solid tumors; CT-2401, a product candidate in preclinical trials for the treatment of liver fibrosis; and in vivo CAR-M cell therapies developed in collaboration with ModernaTX, Inc., to address oncology gene therapies and other cancer targets.

Carisma Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, United States.

Carisma Therapeutics' brand reputation has been negatively impacted by its operational and financial challenges, including the discontinuation of its lead clinical program, a strategic restructuring involving a workforce reduction, and the delisting from Nasdaq. These events suggest setbacks in its clinical development and financial stability, shifting the overall perception towards caution and uncertainty.

The ownership structure of Carisma Therapeutics is a mix of institutional, retail, and individual investors. Approximately 3.90% to 44.27% of the company's stock is held by institutional investors, with major institutional owners including Merck & Co., Inc., Vanguard Group Inc, BlackRock, Inc., Moderna, Inc., TPG GP A LLC, Barclays PLC, Geode Capital Management LLC, Renaissance Technologies LLC, Universal Beteiligungs und Servicegesellschaft mbH, AbbVie Inc., and State Street Corp. Approximately 1.33% to 10.8% of the stock is owned by insiders, with Michael Klichinsky owning the most shares among individual investors. Approximately 94.70% of the company's stock is owned by public companies and individual investors.